The vaccine against the Covid-19 disease developed by the British laboratory AstraZeneca and the University of Oxford requires "
an additional study
", said Thursday, November 26 the chief executive of the group after criticism concerning the announced reliability.
Read also: Covid-19: what strategy to get vaccines accepted?
"
Now that we have found what appears to be better efficacy, we need to validate it, so we need to do further study,
" Pascal Soriot said in an interview with Bloomberg.
>> SEE ALSO -
Covid-19: "Vaccination will not be compulsory", assures Emmanuel Macron